Who decides if Kalshi's clinical trial bets are legal?

Non-advice note: this record is a legal-background review for publication and knowledge-management use. It is not legal advice and does not assess any reader’s specific trading, platform, licensing, enforcement, or compliance position.

Legal-background review note: reviewed for U.S. litigation posture, state gambling-law enforcement posture, CFTC/CEA preemption posture, and market-integrity issue spotting. Last verified: August 5, 2026, 00:00 UTC.

As of August 5, 2026, no court has ruled directly on Kalshi’s clinical-trial event contracts. The practical legal status of the clinical-trial pilot is being inferred from active state gambling suits, CFTC/Commodity Exchange Act preemption litigation over sports contracts, and the CFTC’s pending event-contract rulemaking.

The clinical-trial product matters because it gives regulators something different from election or sports contracts to point at. Kalshi announced biotech prediction markets on July 16, 2026, describing contracts tied to Phase 3 clinical trials, sponsors with market capitalizations of at least $500 million, and listings only after trial enrollment closes.[1] AppliedXL’s public materials describe the resolution apparatus as using public sources such as ClinicalTrials.gov, FDA letters, and advisory committee records.[2] Forbes reported day-one volume of $128,401 for the launch.[3]

Those launch terms do not settle the legal question. They define the target. A court or agency still has to decide whether these contracts are federally protected event contracts, state-regulated gambling, prohibited public-interest contracts, or permissible contracts with a market-integrity problem.

Who has actually decided what

The table is the practical answer. There is no single national sentence that can responsibly read, “Kalshi clinical trial betting is legal,” or “Kalshi clinical trial betting is illegal.” The active documents are doing different work: one court has entered preliminary relief in Washington on gambling-law theories; New York has filed a petition; the Third Circuit has accepted Kalshi’s preemption theory for sports contracts; states are pressing the CFTC from the opposite direction; and the CFTC has proposed a rule that does not neatly classify clinical trials as gaming but does treat health-information leakage as a serious market-integrity issue.

Washington is the immediate injunction problem

The Washington order is the hardest document for Kalshi to talk around because it is not merely an agency press release or a demand letter. On July 21, 2026, the Washington Attorney General announced that King County Superior Court Judge John McHale had found Kalshi’s online gambling likely violates the Washington Gambling Act and the Consumer Protection Act and had rejected Kalshi’s CFTC-preemption defense in granting preliminary injunctive relief.[4]

The word “likely” matters. A preliminary injunction is not a final merits ruling. It reflects the court’s view at an early remedial stage, on the record then before it, and with the standards that govern interim relief. But the remedial consequence is real: a defendant subject to an injunction has to comply with the order unless it is stayed, modified, dissolved, or reversed. For a platform trying to keep markets live, that is not a semantic distinction.

It also matters that Washington’s order, as described in the available public source, arose from the sports-contract fight. A reader interested in clinical-trial contracts cannot lift the Washington result and call it a trial-market ruling. The narrower statement is stronger: Washington has obtained preliminary state-court relief against Kalshi’s online gambling operations and has, at least at that stage, defeated Kalshi’s preemption defense in that forum.[4]

New York is a pleading, not a judgment

New York’s July 31, 2026 petition is the other document creating immediate practical risk. The state seeks an injunction, restitution, penalties, and damages against Kalshi.[5] It alleges that Kalshi is operating an unlicensed gambling business and includes a request for a $100,000 penalty per sports-wagering offer, treble damages, and other relief.[5]

Two numbers in the New York materials should be kept in their procedural lane. New York’s $36 billion exposure figure is the state’s own litigation estimate, not a judicial finding.[5] The petition’s allegations about access by 18-to-20-year-olds are also allegations, not adjudicated facts.[5] Both may be important to a court assessing public interest, harm, or statutory purpose; neither should be written as if a judge has already found it true.

The New York petition also shows why a clinical-trial product can become legally exposed even before a court addresses clinical trials. If a state court accepts the state’s broader theory that Kalshi’s event contracts amount to unlicensed gambling, the remedial order may not need to begin with biotech. It may constrain platform conduct, access, marketing, or categories of contracts in ways that reach future or adjacent markets.

The Third Circuit gives Kalshi its strongest federal answer, but only for the question it decided

Kalshi’s best federal-market-structure argument comes from the Third Circuit. In KalshiEX LLC v. Flaherty, a divided panel held on April 6, 2026, that sports-related event contracts are swaps and that the CEA impliedly preempts New Jersey gambling law as applied to those contracts.[6] That is a serious holding, not merely a company talking point.

It is also not a clinical-trial holding. The subject before the Third Circuit was sports-related event contracts. A clinical-trial contract has a different underlying event, different information asymmetries, different insider-risk profile, and different public-interest record. The preemption reasoning may be invoked by Kalshi in other jurisdictions and for other contracts, but the result has to travel through new facts and new forums.

That distinction is not academic. Washington has rejected Kalshi’s preemption defense at the preliminary-injunction stage, while the Third Circuit accepted it in the New Jersey sports-contract posture.[4][6] Those are not reconcilable by pretending one side is irrelevant. They are signs of an active split in litigation posture across forums and procedural stages.

The state-CFTC fight is broader than any one lawsuit

On July 28, 2026, CNBC reported that 44 state attorneys general told the CFTC it has no authority over sports prediction markets; Florida, Georgia, New Hampshire, Missouri, and Texas were not among the signatories.[7] The letter is not an injunction and not a merits decision. It is still important because it tells courts and the agency that state enforcement officials are not treating the Third Circuit’s preemption analysis as the final word outside that case.

For clinical-trial contracts, that means the jurisdictional fight is likely to arrive before the medical facts are fully tested. A state can frame the platform as an unlicensed gambling operator. Kalshi can answer that federally regulated event contracts occupy the field or impliedly preempt contrary state gambling restrictions. The CFTC can move through rulemaking and enforcement. None of those moves requires the first complaint to be captioned “clinical trials.”

The CFTC proposal likely does less, and more, than the headlines suggest

The CFTC’s June 2026 notice of proposed rulemaking is the document most likely to be overread. Published on June 12, 2026, with comments due July 27, 2026, the proposal would define “gaming” by reference to a recreation or entertainment purpose, rules, and outcomes depending in whole or in part on luck, skill, or athletic ability.[8] A clinical trial outcome does not naturally fit that proposed definition. The result of a Phase 3 trial depends on trial design, biology, patient population, statistical analysis, sponsor conduct, and regulatory process — not on athletic ability or the ordinary characteristics of a game.

That does not make the contracts safe. The same proposal’s public-interest discussion identifies information leakage by insiders, including medical personnel, as a market-integrity concern.[8] For a clinical-trial or FDA-resolution contract, that concern is closer to the center than the gaming definition. Investigators, trial-site personnel, sponsor employees, contract research organizations, data-monitoring participants, regulatory staff, consultants, and vendors may encounter material nonpublic information before the public resolution source appears.

Kalshi’s launch terms appear designed to narrow some of that risk. Listing only after enrollment closes changes the timing.[1] Employment verification addresses one category of potential restricted participation.[1] Public-source resolution reduces the discretion problem at settlement.[2] But those controls are not the same as a court holding or a CFTC final rule. They are facts a regulator or court may examine when deciding whether the market’s structure is adequate.

Clinical-trial markets add an information-integrity problem, not just a gambling-label problem

Sports-contract litigation asks whether a federally regulated event market can be blocked by state gambling law. Clinical-trial contracts ask that too, but they add a second exposure surface: whether people with nonpublic medical, sponsor, trial, or FDA-process information can trade, tip, or influence market outcomes before public resolution.

The CFTC has already signaled that event-contract misconduct is an enforcement concern. Its Enforcement Division issued a February 2026 advisory addressing self-reporting, cooperation, and remediation for violations involving event contracts.[9] The existence of that advisory does not mean a particular clinical-trial contract violates the CEA. It does mean market operators, participants, and information holders should not treat the absence of a clinical-trial-specific injunction as the absence of federal enforcement risk.

Penalty figures circulating around CFTC event-contract enforcement should be handled with care. Available source notes identify inconsistent figures — including $2,246.36 with a five-year suspension, $20,397.58 with a two-year figure, and $6,229.30 with a five-year figure — that appear to describe different disclosed cases. They should not be merged into a single enforcement statistic without checking each primary release.

What can be said responsibly about legality now

A careful legal status statement has to be narrower than the controversy. As of August 5, 2026, Kalshi’s clinical-trial event contracts have not been declared lawful or unlawful by a court. Their status is unsettled, jurisdiction-dependent, and presently controlled by the sports-event-contract preemption fight plus the CFTC’s pending rulemaking.

In Washington, the immediate fact is a preliminary injunction and a state-court rejection of Kalshi’s preemption defense at that stage.[4] In New York, the immediate fact is a pending petition seeking injunctions, restitution, penalties, and damages, not a final judgment.[5] In the Third Circuit, the immediate fact is a precedential sports-contract preemption win for Kalshi against New Jersey gambling-law application, not a clinical-trial ruling.[6] At the CFTC, the immediate fact is a pending proposal whose gaming definition appears poorly matched to clinical trials but whose public-interest factors point directly at health-data insider risk.[8]

That leaves four operating checks for anyone reading the clinical-trial pilot as law rather than product news: identify the jurisdiction; separate an injunction from a complaint or petition; do not convert a sports-contract holding into a clinical-trial holding without analysis; and watch both the CFTC final rule and the state-court injunction records before treating the pilot as settled law.

References

1. Kalshi Biotech Prediction Markets, Kalshi, July 16, 2026.
2. Biopharma Public Probability Report, AppliedXL.
3. Kalshi Opens Betting Market For Pharmaceutical Trials And FDA Decisions, Forbes, July 16, 2026.
4. Judge finds Kalshi’s online gambling likely violates state law, Washington State Office of the Attorney General, July 21, 2026.
5. New York v. KalshiEX LLC petition, New York Attorney General, July 31, 2026.
6. KalshiEX LLC v. Flaherty, No. 25-1922, U.S. Court of Appeals for the Third Circuit, April 6, 2026.
7. 44 states say CFTC has no authority over sports prediction markets, CNBC, July 28, 2026.
8. Prediction Markets; Public Interest Determinations, Federal Register, June 12, 2026.
9. CFTC Division of Enforcement Issues Advisory Regarding Event Contracts, Commodity Futures Trading Commission, 2026.